Poddubnaya, Irina V.

Issue Section Title Abstract File
Vol 21, No 4 (2019) CLINICAL ONCOLOGY The role of second generation Bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Resolution Abstract PDF
(Rus)
Vol 22, No 1 (2020) CLINICAL ONCOLOGY Solitary (extramedullary) plasmocytoma. Clinical recommendations Abstract PDF
(Rus)
Vol 22, No 1 (2020) CLINICAL ONCOLOGY ELEVATE-TN Study. New data of acalabrutinib in first-line treatment of chronic lymphocytic leukemia. Resolution Abstract PDF
(Rus)
Vol 22, No 1 (2020) CLINICAL ONCOLOGY Modern view on the issues of diagnosis and verification of axillary lymph nodes involvement in early breast cancer Abstract PDF
(Rus)
Vol 22, No 2 (2020) Conference Proceedings Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic Abstract PDF
(Rus)
Vol 22, No 2 (2020) Original Article Maintenance oncohematological patients and new coronavirus infection: experience of the City Clinical Hospital №52 Abstract PDF
(Rus)
Vol 22, No 2 (2020) Conference Proceedings New opportunities of systemic therapy of CD30-positive primary cutaneous T-cell lymphomas Abstract PDF
(Rus)
Vol 22, No 2 (2020) Review Accompanying therapy in oncohematological patients with secondary immunodeficiency Abstract PDF
(Rus)
Vol 22, No 2 (2020) Best Practice Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience Abstract PDF
(Rus)
PDF
(Eng)
Vol 22, No 2 (2020) Original Article First-line therapy of indolent non-Hodgkin’s lymphoma in routine clinical practice Abstract PDF
(Rus)
Vol 22, No 4 (2020) CLINICAL ONCOLOGY Multiple myeloma Abstract PDF
(Rus)
Vol 22, No 4 (2020) CLINICAL ONCOLOGY The virtual forum on the diagnosis and treatment of PIK3CA-mutated metastatic breast cancer. October 16th, 2020. Event review Abstract PDF
(Rus)
Vol 22, No 4 (2020) CLINICAL ONCOLOGY Interim results of a multicenter retrospective-prospective observational post-marketing study of Extimia® BIOCAD (INN: empegfilgrastim) to evaluate safety and efficacy in patients with lymphoproliferative diseases receiving cytotoxic therapy Abstract PDF
(Rus)

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies